Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2019-12-01
Serie:	Frontiers in Medicine
Soggetti:	PTLD alloHSCT aggressive lymphoma brentuximab vedotin (BV) third-party EBV-specific T-lymphocytes
Accesso online:	https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!